Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study.
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA10502-LBA10502
Keyword(s):
LBA10502 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA10008-LBA10008
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA5002-LBA5002
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. 4-4
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA2010-LBA2010
◽
Keyword(s):
2017 ◽
Vol 35
(15_suppl)
◽
pp. LBA10004-LBA10004
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. CRA3503-CRA3503
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA8500-LBA8500
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA4003-LBA4003
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA4004-LBA4004
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA4003-LBA4003
◽